Seagen SGEN announced that it has entered into a definitive agreement to be acquired by pharma bigwig Pfizer PFE for $229 per share, marking a 33% premium over Seagen’s Friday’s closing price in cash ...
Drugmaker Merck & Co is reportedly in advanced talks to buy cancer-focused biotech company Seagen Inc. The deal could be worth roughly $40 billion or more, according to the Wall Street Journal. A deal ...
Pfizer Inc. is purchasing cancer-drug maker Seagen Inc. for an enterprise value of $43 billion, using the biggest deal of the year to set its course out of the pandemic and back into mainstream pharma ...
Daiichi Sankyo was ordered to pay Seagen $42 million in their antibody-drug conjugate patent lawsuit. Gene therapy delivery CDMO VectorBuilder will build a $500 million campus in China. Legend Biotech ...
Biopharma acquisitions often come with layoffs and lab shutdowns as smaller companies get absorbed. Whether that happens to Seagen is a big question that will impact the Seattle-area biotech community ...
– Seagen Licenses Disitamab Vedotin, a Novel HER2-targeted Antibody-Drug Conjugate (ADC) from RemeGen – – Disitamab Vedotin has Shown Potential as a Differentiated ADC Across a Range of HER2 ...
Merck's buyout of Seagen talk has disappeared. Sales of approved therapies continue to ramp. Recent approvals and pipelines are mostly priced in. Seagen Q3 2022 results were reported on October 27, ...
Seattle-area biotech experts are eying the past warily in the wake of this week’s news that Pfizer plans to acquire Bothell, Wash.-based Seagen for a whopping $43 billion. Most previous acquisitions ...
Seagen Inc. and Lava Therapeutics NV have entered into an exclusive license agreement under which Seagen will work to develop, manufacture and commercialize LAVA-1223, a bispecific T-cell engager ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback